Dr. Valantine is the NIH inaugural Chief Officer for Scientific Workforce Diversity, and a senior scientist in the intramural research program. She was recruited as a nationally recognized scientist to develop a comprehensive vision and strategies
to diversify scientific applicant pools and pipelines, to expand recruitment methods and retention strategy, and to help promote inclusiveness and equity throughout the biomedical research community at large. Prior to starting this position in April
2014, Dr. Valantine was Professor of Cardiovascular Medicine and the Senior Associate Dean for Diversity and Leadership at Stanford School of Medicine, a leadership position she held since November 2004. She is nationally recognized for her transformative
approaches to diversity, and is a recipient of the NIH Director?s Pathfinder Award for diversity in the scientific workforce. In this research effort she studied interventions for stereotype threat, which she proposed is an important factor that
impedes the advancement of women in academic medicine. She has also pioneered new models to better align the academic work place with the needs of faculty in the 21st Century, for which Stanford gained national recognition as the recipient of the
Alfred P. Sloan Award for faculty career flexibility. The model, Academic Biomedical Career Customization (ABCC), has received widespread attention with articles in Harvard Business review, New York Times, Nature, Chronicle of Higher Education and
Originally from The Gambia, West Africa, Dr. Valantine majored in biochemistry and studied medicine at St. George?s Hospital, London University. After completing internal medicine residency, she obtained her cardiology fellowship training at Royal
Postgraduate Medical School, London. For her post-doctoral research fellowship training she moved to Stanford University, and undertook research focused on Echocardiography for the diagnosis of acute rejection. Dr. Valantine has maintained an active
clinical research program that continues to yield high impact transformations in patient care. She was the Principle Investigator (PI) in a New England Journal of Medicine, (April 2010) article reporting a non-invasive approach for the diagnosis
of acute heart transplant rejection, an innovation that represented a major paradigm shift in the way heart transplant patients are managed. She was the PI for an NIH-funded study in which she proposed (and confirmed) that the organ transplant is
essentially a genome transplant, and that monitoring the level of donor DNA in the recipient?s blood as a marker of organ damage will detect early stages of rejection, published in Science Translational Medicine (June, 2014).
She has been the recipient of several research grants from the NIH and AHA, and has authored over 160 peer-reviewed publications in high impact journals including NEJM, PNAS, Cell, Science Translational Medicine, Circulation, Transplantation, Journal
of Heart & Lung Transplant, 10 book chapters, and has been invited to be a presenter at over 100 lectures. She has served on many editorial boards including Journal of Heart & Lung Transplant, Transplantation and Circulation. She is a Past-President
of the American Heart Association Western States Affiliate Board of Directors.
She is married to Denis von Kaeppler whose background is in Information Technology. They have two daughters. Aside from research and diversity, Dr. Valantine has a passion for travel, sailing, fine dining, visits to spas, and exercise.